J&J bows out of RSV vac­cine race, end­ing PhI­II study and ced­ing to Pfiz­er, GSK

John­son & John­son an­nounced Wednes­day morn­ing it is end­ing de­vel­op­ment of its adult RSV vac­cine that was in the mid­dle of a 27,200-pa­tient tri­al, giv­ing up a big slice of what’s ex­pect­ed to be the next multi­bil­lion-dol­lar phar­ma mar­ket.

The de­ci­sion came down to the shift­ing RSV “com­pet­i­tive land­scape,” a com­pa­ny spokesper­son tells End­points News, adding the “breadth of op­tions” was much dif­fer­ent than when J&J first start­ed its piv­otal study. The spokesper­son de­clined to com­ment on the Phase III da­ta, say­ing on­ly the shot is un­der­go­ing an “on­go­ing as­sess­ment.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER